Results 351 to 360 of about 23,313,489 (418)

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2. [PDF]

Cancers (Basel)
Montesinos P, Buccisano F, Cluzeau T, Vennström L, Heuser M.   +4 more
europepmc   +1 more source

A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma. [PDF]

Ann Hematol
Abd El-Ghani SE, Abido HY, Tawfik NM, Shaheen G, Ellithy HN.   +4 more
europepmc   +1 more source

Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. [PDF]

Signal Transduct Target Ther
Zai W, Yang M, Jiang K, Guan J, Wang H, Hu K, Huang C, Chen J, Fu W, Zhan C, Yuan Z.   +10 more
europepmc   +1 more source

CD38 in SLE CD4 T cells promotes Ca²⁺ flux and suppresses interleukin-2 production by enhancing the expression of GM2 on the surface membrane. [PDF]

Nat Commun
Katsuyama E, Humbel M, Suarez-Fueyo A, Satyam A, Yoshida N, Kyttaris VC, Tsokos MG, Tsokos GC.   +7 more
europepmc   +1 more source

Plasma Levels of Interleukin 2 (IL-2) Associated with Hearing Loss Evaluation in the Elderly.

Noise Health
Cordeiro FP, Marchiori LLM, Teixeira DC, Andraus RAC, Poli-Frederico RC.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interleukin-2

Reactions weekly, 2013
Howard L. Kaufman, Benjamin Kelley, Eduardo Braun   +2 more
openaire   +2 more sources

The Interleukin -2

Acta Clinica Belgica, 1987
SummaryDiscovered in 1976, the lymphokine interleukin-2, intensively studied during the last years, plays a major role in the regulation of the immune function. The authors reviewing its principal properties, anticipate forthcoming prospects of considerable implications in therapy.Acta Clin. Bclg. 42, 4: 255–68.
M. Hiden, P. Neve
openaire   +3 more sources

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

New England Journal of Medicine, 1987
We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus interleukin-2 or therapy with high-dose interleukin-2 alone in 157 patients with metastatic cancer for whom standard therapy had proved ineffective or no ...
S. Rosenberg, M. Lotze, L. Muul, A. E. Chang, F. Avis, S. Leitman, W. Linehan, C. Robertson, R. Lee, J. Rubin, C. Seipp, Colleen G. Simpson, D. White   +12 more
semanticscholar   +1 more source

Interleukin-2, Interleukin-15, and Their Receptors

International Reviews of Immunology, 1998
Both IL-15 and IL-2 are 14-15 kDa members of the four alpha-helical bundle family of cytokines that have T cell growth factor activity. In contrast to the pattern manifested by IL-2, IL-15 mRNA is produced by a wide variety of tissues other than T cells. We have demonstrated that IL-15 expression is posttranscriptionally regulated by multiple elements,
Thomas A. Waldmann, Richard N. Bamford, Yutaka Tagaya   +2 more
openaire   +3 more sources

Interleukin-2 toxicity. [PDF]

Journal of Clinical Oncology, 1991
Because of the ability of interleukin-2 (IL-2) to support the proliferation and activation of numerous types of immunocompetent cells and to support the survival of adoptively transferred lymphocytes, there has been considerable interest in its use in the immunotherapy of malignancies.
Jay P. Siegel, Roj K. Puri
openaire   +2 more sources